146 related articles for article (PubMed ID: 31702999)
1. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
2. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
3. Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.
Padovan M; Caccese M; Zagonel V; Lombardi G
Anticancer Drugs; 2021 Feb; 32(2):218-221. PubMed ID: 33395066
[TBL] [Abstract][Full Text] [Related]
4. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
5. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
6. Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology.
Mann SA; Cheng L
Expert Rev Anticancer Ther; 2020 Jan; 20(1):1-4. PubMed ID: 31842633
[No Abstract] [Full Text] [Related]
7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma.
Cheung AH; Chow C; Yu MY; Law WW; Law PP; Choi PC; Kang W; To KF
Pathology; 2019 Jan; 51(1):67-73. PubMed ID: 30502217
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
[TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review.
Jenkins TM; Hanley KZ; Schwartz LE; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2020 Jun; 44(6):782-792. PubMed ID: 31934920
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of mismatch repair deficiency in gallbladder cancer.
Goeppert B; Roessler S; Renner M; Loeffler M; Singer S; Rausch M; Albrecht T; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
Diagn Pathol; 2019 May; 14(1):36. PubMed ID: 31068195
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
González I; Goyal B; Xia MD; Pai RK; Ma C
Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
[TBL] [Abstract][Full Text] [Related]
15. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
16. Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature.
Seltzer J; Lucas J; Commins D; Lerner O; Lerner A; Carmichael JD; Zada G
Neurosurg Focus; 2015 Feb; 38(2):E10. PubMed ID: 25639312
[TBL] [Abstract][Full Text] [Related]
17. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
18. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.
Zacharia BE; Gulati AP; Bruce JN; Carminucci AS; Wardlaw SL; Siegelin M; Remotti H; Lignelli A; Fine RL
Neurosurgery; 2014 Apr; 74(4):E447-55; discussion E455. PubMed ID: 24226425
[TBL] [Abstract][Full Text] [Related]
19. Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies.
Ju JY; Dibbern ME; Mahadevan MS; Fan J; Kunk PR; Stelow EB
Am J Clin Pathol; 2020 Apr; 153(5):598-604. PubMed ID: 31844887
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Sol B; de Filette JMK; Awada G; Raeymaeckers S; Aspeslagh S; Andreescu CE; Neyns B; Velkeniers B
Eur J Endocrinol; 2021 Jan; 184(1):K1-K5. PubMed ID: 33112279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
